Teva Pharmaceutical Industries Limited (TLV:TEVA)
6,186.00
+211.00 (3.53%)
Feb 20, 2025, 5:24 PM IDT
TLV:TEVA Revenue
In the year 2024, Teva Pharmaceutical Industries had annual revenue of $16.54B USD with 4.40% growth. Teva Pharmaceutical Industries had revenue of $4.23B in the quarter ending December 31, 2024, a decrease of -5.12%.
Revenue
$16.54B
Revenue Growth
+4.40%
P/S Ratio
n/a
Revenue / Employee
$463.60K
Employees
35,686
Market Cap
68.37B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Danel (Adir Yeoshua) | 2.71B |
Kamada | 588.75M |
Bait Bakfar | 102.08M |
Novolog (Pharm-Up 1966) | 1.73B |
Ilex Medical | 982.96M |
BrainsWay | 143.60M |
SofWave Medical | 210.53M |
Golden House | 47.96M |
Teva Pharmaceutical Industries News
- 16 hours ago - Teva Pharmaceutical Industries Ltd (TEVA) Launches SELARSDI⢠in the U.S. - GuruFocus
- 1 day ago - Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease - GlobeNewsWire
- 1 day ago - Final Trade: TEVA, JNJ, TJX, BABA - CNBC
- 2 days ago - Teva/Alvotech follow Amgen in launching biosimilar for J&J’s Stelara - Seeking Alpha
- 2 days ago - Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara - Reuters
- 2 days ago - Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. - GlobeNewsWire
- 2 days ago - Corcept accused in California of stifling Teva’s generic launch - Seeking Alpha
- 4 days ago - Teva Pharmaceutical Industries Ltd (TEVA) and Alvotech Announce FDA Review of Biosimilar Application - GuruFocus